Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility

American Journal of Public Health

Volumn 96, Issue 5, 2006, Pages 770-773

  Wood, Evan ^a,b   Tyndall, Mark W ^a   Qui, Zhenguo ^c   Zhang, Ruth ^c   Montaner, Julio S G ^a   Kerr, Thomas ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; ILLICIT DRUG; METHADONE;

ADULT; ARTICLE; CANADA; CITY; DRUG DEPENDENCE; DRUG OVERDOSE; EVALUATION; FEMALE; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYGIENE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; NURSE; OUTCOME ASSESSMENT; SAFETY; SYRINGE; VANCOUVER SAFER INJECTING FACILITY;

AMBULATORY CARE FACILITIES; BRITISH COLUMBIA; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEEDLE-EXCHANGE PROGRAMS; OVERDOSE; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33646260200     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2004.057828     Document Type: Article

References (24)

1. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001;161:1281-1288.
2. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274: 1226-1231.
3. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17: 887-893.
4. Garfield J, Drucker E. Fatal overdose trends in major US cities: 1990-1997. Addictions Research and Theory. 2001;9:425-436.
5. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 2001;165:405-410.
6. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction. 2003; 98:739-747.
7. Dolan K, Kimber J, Fry C, Fitzgerald J, McDonald D, Frautmann F. Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug Alcohol Rev. 2000;19:337-346.
8. Kimber J, Dolan K, van Beek I, Hedrich D, Zurhold H. Drug consumption facilities: an update since 2000. Drug Alcohol Rev. 2003;22:227-233.
9. Wood E, Kerr T, Montaner JS, et al. Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis. 2004; 4:301-306.
10. Wood E, Kerr T, Lloyd-Smith E, et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J. 2004;1:9.
11. Spittal PM, Craib KJ, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002; 166:894-899.
12. Miller CL, Spittal PM, LaLiberte N, et al. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs. J Acquir Immune Defic Syndr. 2002;30:335-341.
13. Wood E, Tyndall MW, Spittal PM, et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS. 2002;16:941-943.
14. Corneil TA, Kuyper LM, Shovellor J, et al. Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place. 2006;12:79-85.
15. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2001;28:351-357.
16. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997; 11:F59-F65.
17. Kerr T, Tyndall M, Li K, Montaner JS, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;40:1153-1167.
18. Wood E, Spittal PM, Kerr T, et al. Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can J Public Health. 2003;94:355-359.
19. Kerr T, Wood E, Small D, Palepu A, Tyndall MW. Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. CMAJ. 2003;169:759-763.
20. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999;13:1807-1818.
21. Wood E, Kerr T, Small W, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004;171:731-734.
22. Christie T, Wood E, Schechter MT, O'Shaughnessy MV. A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects. Int J Drug Policy. 2003;15:66-73.
23. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999;353:1657-1661.
24. Broadhead RS, Kerr TH, Grund JPC, Altice FL. Safer injection facilities in North America: their place in public policy and health initiatives. J Drug Issues. 2002;32:329-355.